Return to PCORI.org 
Symptom Management for Patients with Advanced Illness PFA
This content provides additional insight specific to the Symptom Management for Patients with Advanced Illness PFA, originally released in Cycle 2 2017 and re-released in Cycle 2 2018.
- Are complementary therapies considered acceptable for this PFA?
- Does PCORI provide salary support for patients/stakeholders who are part of the study team?
- Does the funding cover costs for interventions and associated patient care costs?
- Does the $2 million include PCORI's indirect cost rate?
- Are insurers or payers considered acceptable partners?
- How are engagement efforts best described in an application?
- Is there a minimum expected sample size?
- Are there specific outcome measures of interest for this PFA?
- The funding announcement says that candidate interventions should be efficacious and/or widely used. What does that mean?
- Must There Be A Pharmacological Agent Proposed as a Comparator?
- Are the symptoms listed in the PFA the only ones that can be proposed to study?
- How is “advanced illness” defined for this PFA? Are chronic illnesses such as diabetes or hypertension potential patient populations of interest?